United Therapeutics Corporation (UTHR)

Market Cap	11.00B
Revenue (ttm)	2.33B
Net Income (ttm)	984.80M
Shares Out	47.06M
EPS (ttm)	19.81
PE Ratio	11.80
Forward PE	9.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	355,916
Open	236.59
Previous Close	235.95
Day's Range	233.64 - 237.53
52-Week Range	204.44 - 261.54
Beta	0.55
Analysts	Strong Buy
Price Target	292.67 (+25.15%)
Earnings Date	May 1, 2024

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 1,168
• Stock Exchange: NASDAQ
• Ticker Symbol: UTHR

Financial Performance

In 2023, UTHR's revenue was $2.33 billion, an increase of 20.20% compared to the previous year's $1.94 billion. Earnings were $984.80 million, an increase of 35.40%.

Analyst Forecast

According to 9 analysts, the average rating for UTHR stock is "Strong Buy." The 12-month stock price forecast is $292.67, which is an increase of 25.15% from the latest price.

Price Target

$292.67

(25.15% upside)

Analyst Consensus: Strong Buy